Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Biotech/Pharma News
-
By Kevin E. Noonan — The significance of single nucleotide polymorphisms (SNPs) has been appreciated in genetic research ever since the discovery in the early 1980’s that SNPs could produce genetic markers known as restriction fragment length polymorphisms (RFLPs). However, although this type of polymorphism is responsible for well-recognized genetic mutations (for example,…
-
By Kevin E. Noonan — The economic and political realities (both at home and abroad) are beginning to be felt with regard to intellectual property protections for Western companies in poor and developing nations, as evidenced by changes to American trade policies announced recently (see "Worldwide Drug Pricing Regime in Chaos"). Specifically, the…
-
By Kevin E. Noonan — James Surowiecki, who writes a weekly column called "The Financial Page" in The New Yorker magazine and is the author of "The Wisdom of Crowds," doesn’t like patents. He complained about business method patents in his column in the July 14, 2003 edition of the magazine (see "Patent…
-
By Donald Zuhn — On Tuesday, Massachusetts Governor Deval Patrick (at right) outlined his Massachusetts Life Science Strategy, a $1 billion funding initiative intended to spur new medical and science research, strengthen investment and create new jobs in these fields, produce new therapies, and establish a stem cell bank. Governor Patrick unveiled the…
-
By Kevin E. Noonan — The crisis regarding the pricing of patented drugs in poor and developing countries continues this week, with actions by current and former U.S. chief executives contributing to the situation. The U.S. Trade Representative issued a "Special 301 Report" on Monday, pursuant to the provisions of the Trade Act…
-
By Kevin E. Noonan — Treaties have a funny way of not having the results expected when they are signed. The Versailles Treaty and the Briand-Kellogg Pact did not prevent Germany from rearming prior to World War II; the United Nations Charter did not prevent the General Assembly from adopting resolutions contrary to…
-
By Kevin E. Noonan — There is a growing trend in developing countries (such as Brasil, China, India, and Thailand) for their governments to avail themselves of the ability under prevailing international trade agreements to grant compulsory licenses or permit so-called "parallel imports" of generic drugs in the face of national patents procured…
-
By Kevin E. Noonan — In just the latest in a series of developments unwelcomed by Western drug companies, Brasil has threatened to distribute a generic version of Merck & Co.’s anti-AIDS drug efavirenz (Stocrin®). This action is consistent with earlier steps taken by Brasil, as well as Thailand, that thwart the intentions…
-
By Kevin E. Noonan — The sanctimony continues over the U.S. Patent and Trademark Office re-examination of the Thomson stem cell patents. This time, it is an article by Constance Holden in the April 13, 2007 issue of Science. Although refreshingly factual, it manages in ways both frank and subtle to create the…
-
By Mark Chael — On Friday, April 27, 2007 at 9:00 am, the Seton Hall University School of Law (SHU Law) will hold a press conference to announce the establishment of the Center for Health & Pharmaceutical Law. The mission of the new Center will be "to address the evolving legal and public…
Patent Docs 